As of September 30, 2026, Ascendis Pharma A/S carries a market capitalization of 13.25B, placing it among publicly traded companies globally. Its enterprise value stands at 12.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 13.25B |
| Enterprise Value | 12.73B |
Ascendis Pharma A/S's next confirmed earnings release is scheduled for February 17, 2027.
| Earnings Date | 2/17/2027 |
As of September 30, 2026, Ascendis Pharma A/S has 65.60M shares outstanding.
| Shares Outstanding | 65.60M |
As of September 30, 2026, Ascendis Pharma A/S trades at a trailing price-to-earnings ratio of 14.56. The price-to-sales ratio is 10.61, and the price-to-book ratio stands at 8.83.
| PE Ratio | 14.56 |
| PS Ratio | 10.61 |
| PB Ratio | 8.83 |
| P/TBV Ratio | 8.85 |
| P/FCF Ratio | 25.02 |
| P/OCF Ratio | 23.81 |
As of September 30, 2026, Ascendis Pharma A/S trades at an EV/EBITDA multiple of 31.99 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 10.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 33.53 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.73B versus a market cap of 13.25B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 10.58 |
| EV / EBITDA | 31.99 |
| EV / EBIT | 33.53 |
As of September 30, 2026, Ascendis Pharma A/S maintains a current ratio of 2.89, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.84, indicating elevated leverage, while an interest coverage ratio of 3.49 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 2.89 |
| Quick Ratio | 2.22 |
| Debt / Equity | 29.84 |
| Debt / EBITDA | 1.13 |
| Interest Coverage | 3.49 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) stands at 48.95, measuring how efficiently the asset base is converted into earnings. Inventory turnover of 0.31 indicates how many times Ascendis Pharma A/S sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | 48.95 |
| Inventory Turnover | 0.31 |
Over the twelve months ended September 30, 2026, Ascendis Pharma A/S recorded an income tax benefit of -608.14M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 268.58M, leaving 876.72M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | -608.14M |
These figures are as of the close on November 17, 2026.
| 50-Day Moving Average | 215.65 |
Over the twelve months ended September 30, 2026, Ascendis Pharma A/S generated 1.20B in revenue and converted that into 876.72M in net income, yielding earnings per share of 13.36. EBITDA reached 398.00M, while operating income came in at 376.30M.
| Revenue | 1.20B |
| Gross Profit | 1.11B |
| Operating Income | 376.30M |
| Pretax Income | 268.58M |
| Net Income | 876.72M |
| EBITDA | 398.00M |
| EBIT | 379.75M |
| Earnings Per Share (EPS) | 13.36 |
As of September 30, 2026, Ascendis Pharma A/S holds 964.36M in cash and equivalents against 447.81M in total debt, resulting in a net debt position of -516.56M. Total book value stands at 1.50B, with working capital of 1.04B providing operational flexibility.
| Cash & Cash Equivalents | 964.36M |
| Total Debt | 447.81M |
| Net Debt | -516.56M |
| Equity (Book Value) | 1.50B |
| Book Value Per Share | 22.87 |
| Working Capital | 1.04B |
Ascendis Pharma A/S produced 536.15M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -6.15M in capital expenditures, free cash flow totaled 530.00M - equivalent to 8.39 per share.
| Operating Cash Flow | 536.15M |
| Capital Expenditures | -6.15M |
| Free Cash Flow | 530.00M |
| FCF Per Share | 8.39 |
Over the twelve months ended September 30, 2026, Ascendis Pharma A/S posted a gross margin of 91.93, reflecting its pricing power and cost economics. The operating margin of 31.28 and net profit margin of 72.88 provide insight into operational efficiency.
| Gross Margin | 91.93 |
| Operating Margin | 31.28 |
| Pretax Margin | 22.33 |
| Profit Margin | 72.88 |
| EBITDA Margin | 33.08 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 4.00, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.85, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Ascendis Pharma A/S shareholders.
| Shareholder Yield | 0.85 |
| FCF Yield | 4.00 |
Already premium?